Advertisement Neuropore, UCB partner to develop new treatment for Parkinson’s disease - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Neuropore, UCB partner to develop new treatment for Parkinson’s disease

US-based Neuropore Therapies has entered into a nagreement with Belgian biopharmaceutical firm UCB to develop and commercialize therapeutic products to slow the progression of Parkinson’s disease (PD) and related disorders.

As part of the deal, UCB will receive the world-wide exclusive license to develop and commercialize Neuropore’s new small molecule NPT200-11in all indications.

NPT200-11 that targets pathogenic alpha-synuclein which is currently in preclinical development and the companies will work together to complete non-clinical studies, with the first Phase I trial scheduled to be started in 2015.

UCB New Medicines president Ismail Kola said: "Parkinson’s disease is a debilitating neurodegenerative disorder that results in disruption of normal movement and motor function, as well as cognitive and other life-altering symptoms.

"People living with Parkinson’s disease need better treatment options, especially as there is currently no approved treatment that addresses a fundamental pathological mechanism in Parkinson’s disease.

"With Neuropore’s NPT200-11, we have the opportunity to develop a disease modifying treatment option for patients with Parkinson’s disease and other synucleinopathies."

The deal will see an initial upfront payment of $20m made to Neuropore, which is also entitled to potential development, regulatory and sales-based milestones payments, of up to a potential total of $460, in addition to royalties on net sales.

Neuropore CEO Dieter Meier said: "By working together we wish to accelerate the development of new treatments that can halt or slow the progression of Parkinson’s disease and other neurodegenerative diseases for patients who suffer from such debilitating conditions.

"UCB’s commitment and expertise in this field offers the best opportunity to collaboratively develop orally available small molecules to treat diseases that affect large patient populations and possibly certain orphan diseases."